2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Tarlatamab was associated with significant improvements in overall survival (OS), progression-free survival (PFS) and patient-reported outcomes (PROs) vs standard-of-care (SoC) chemotherapy in patients with small-cell lung cancer (SCLC) undergoing second-line (2L) therapy, according to the primary analysis of the phase III DeLLphi-304 study presented at ASCO 2025.

Tumour treating fields (TTFields) added to first-line chemotherapy (gemcitabine and nab-paclitaxel [GnP]) extends survival in individuals with locally advanced pancreatic adenocarcinoma (LA-PAC) in the PANOVA-3 study.

The combination of niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) results in significant improvements in radiographic progression-free survival (rPFS) and time to symptomatic progression (TSP) in metastatic castration-sensitive prostate cancer (mCSPC) patients with alterations in homologous recombination repair (HRR) genes, as shown by the results of the phase III AMPLITUDE trial.

In the primary analysis of the ASCENT-04/KEYNOTE-D19 study, a combination regimen comprising sacituzumab govitecan (SG) and pembrolizumab delivers significant progression-free survival (PFS) benefit in women with previously untreated PD-L1+ advanced triple-negative breast cancer (TNBC).